Kestra Medical Technologies, Ltd. (KMTS) Cash Flow Statement
Where KMTS’s cash came from and went, FY2026
April 30, 2026 · U.S. dollars- Cash from operations
- −$81.7M
- Capital expenditures
- $34.9M 36.7% of revenue
- Free cash flow
- −$116.6M −122.6% margin
- Returned to shareholders
- $3.1M
- Change in cash
- −$137.9M cash at year-end $100.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
KMTS operating cash flow, capex and free cash flow
KMTS cash flow trends, FY2020–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$30.3MFY2020 | −$81.7MFY2026 | — | |
| Capital expenditures | $232,000FY2020 | $34.9MFY2026 | +172.6%/yr | |
| Free cash flow | −$30.5MFY2020 | −$116.6MFY2026 | — | |
| Free cash flow margin | −1,115.4%FY2023 | −122.6%FY2026 | +992.8 pts | |
| Stock-based compensation | $0FY2020 | $33.6MFY2026 | — | |
| Dividends paid | $183,000FY2020 | $323,000FY2026 | +12.0%/yr | |
| Capex / revenue | 202.6%FY2023 | 36.7%FY2026 | −166.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KMTS cash flow by activity
KMTS net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
KMTS cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$131.6M | −$113.8M | −$94.1M | −$84.2M | −$34.1M | −$29.5M |
| Depreciation & amortization | $8.7M | $8.0M | $11.6M | $4.9M | $420,000 | $478,000 |
| Stock-based compensation | $33.6M | $24.3M | $1.5M | $1.2M | $1.9M | $0 |
| Change in working capital | −$685,000 | −$6.2M | $4.4M | $1.3M | −$19,000 | −$2.0M |
| Other non-cash items | $8.2M | $10.2M | $4.4M | $7.2M | $1.9M | $706,000 |
| Cash from operating activities | −$81.7M | −$77.6M | −$72.2M | −$69.6M | −$29.9M | −$30.3M |
| Investing activities | ||||||
| Capital expenditures | −$34.9M | −$23.6M | −$12.5M | −$15.5M | −$336,000 | −$232,000 |
| Investments (net) | −$168.0M | −$23.3M | −$12.2M | −$15.5M | −$334,000 | −$232,000 |
| Acquisitions & other investing | −$344,000 | $23.6M | $12.5M | $15.5M | $336,000 | $232,000 |
| Cash from investing activities | −$203.3M | −$23.3M | −$12.2M | −$15.5M | −$334,000 | −$232,000 |
| Financing activities | ||||||
| Dividends paid | −$323,000 | −$1.7M | −$799,000 | −$671,000 | −$187,000 | −$183,000 |
| Share repurchases & issuance (net) | −$2.8M | — | — | — | — | — |
| Net borrowing (repayment) | — | $0 | $5.9M | −$5.3M | $20.0M | — |
| Shares issued | $149.3M | $319.2M | $75.0M | $102.1M | $0 | $0 |
| Other financing | $916,000 | $12.7M | −$2.4M | $0 | $29.0M | $30.4M |
| Cash from financing activities | $147.1M | $330.3M | $77.7M | $96.1M | $48.8M | $30.2M |
| Summary | ||||||
| Net change in cash | −$137.9M | $229.3M | −$6.7M | $11.0M | $18.6M | −$286,000 |
| Cash at end of period | $100.0M | $237.9M | $8.6M | $15.3M | $24.9M | $6.3M |
| Free cash flow | −$116.6M | −$101.2M | −$84.7M | −$85.1M | −$30.2M | −$30.5M |
| Free cash flow margin | −122.6% | −169.2% | −304.7% | −1,115.4% | — | — |
| Capex / revenue | 36.7% | 39.4% | 45.0% | 202.6% | — | — |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Jul '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$44.1M | −$38.8M | −$34.2M | −$32.8M | −$25.8M | −$51.1M | −$21.8M | −$20.6M | −$20.3M | −$22.3M | −$21.6M | −$13.1M |
| Depreciation & amortization | $2.7M | $2.3M | $2.0M | $2.4M | $2.0M | $1.8M | $1.9M | $1.9M | $2.4M | $3.5M | $3.4M | $75,000 |
| Stock-based compensation | $9.5M | $10.3M | $10.1M | $8.7M | $4.6M | $22.3M | $459,000 | $1.1M | $377,000 | $389,000 | $372,000 | $956,000 |
| Change in working capital | −$7.5M | $4.9M | $2.1M | $711,000 | −$6.0M | −$3.5M | −$360,000 | −$1.4M | −$1.4M | $2.7M | $1.5M | −$364,000 |
| Other non-cash items | $7.1M | $2.6M | $1.6M | $2.7M | −$1.1M | $6.7M | $1.8M | $1.0M | $1.5M | $740,000 | $612,000 | $948,000 |
| Cash from operating activities | −$32.3M | −$18.7M | −$18.4M | −$18.3M | −$26.3M | −$23.7M | −$18.0M | −$18.0M | −$17.5M | −$14.9M | −$15.8M | −$11.5M |
| Investing activities | ||||||||||||
| Capital expenditures | −$8.3M | −$9.7M | −$9.8M | −$7.3M | −$8.2M | −$8.0M | −$4.5M | −$4.4M | −$7.1M | −$4.2M | −$5.0M | −$1.8M |
| Investments (net) | −$13.0M | −$163.0M | — | — | −$8.2M | −$7.8M | −$4.1M | −$4.5M | −$7.0M | −$4.2M | −$5.0M | — |
| Acquisitions & other investing | $0 | −$1,000 | −$5.1M | −$155,000 | $8.2M | $8.0M | $4.1M | $4.4M | $7.1M | $4.2M | $5.0M | $0 |
| Cash from investing activities | −$21.4M | −$172.7M | −$14.9M | −$7.4M | −$8.2M | −$7.8M | −$4.5M | −$4.5M | −$7.0M | −$4.2M | −$5.0M | −$1.8M |
| Financing activities | ||||||||||||
| Dividends paid | −$172,000 | −$298,000 | −$25,000 | $0 | $0 | −$6,000 | −$50,000 | −$575,000 | −$1.0M | −$263,000 | −$110,000 | −$56,000 |
| Net borrowing (repayment) | $28.6M | — | — | — | $0 | $0 | $0 | — | — | — | — | — |
| Shares issued | $0 | $0 | $149.3M | $0 | $0 | $215.8M | $0 | $0 | $103.4M | $12.5M | $12.5M | $0 |
| Other financing | −$5.9M | $113,000 | −$84,000 | −$27,000 | −$1.9M | −$1.1M | −$69,000 | $0 | $13.9M | −$1,000 | −$493,000 | $157,000 |
| Cash from financing activities | $22.5M | −$185,000 | $149.2M | −$27,000 | −$1.9M | $214.7M | −$119,000 | −$575,000 | $116.3M | $12.2M | $11.9M | $101,000 |
| Summary | ||||||||||||
| Net change in cash | −$31.2M | −$191.6M | $115.9M | −$25.8M | −$36.4M | $183.2M | −$22.6M | −$23.1M | $91.7M | −$6.9M | −$8.9M | −$13.3M |
| Cash at end of period | $68.9M | $100.0M | $291.7M | $175.8M | $201.5M | $237.9M | $54.7M | $77.3M | $100.3M | $8.6M | $15.5M | $11.6M |
| Free cash flow | −$40.6M | −$28.4M | −$28.2M | −$25.6M | −$34.4M | −$31.7M | −$22.4M | −$22.5M | −$24.6M | −$19.1M | −$20.8M | −$13.4M |
| Free cash flow margin | −131.2% | −99.1% | −114.7% | −113.5% | −177.8% | −184.2% | −148.8% | −152.6% | −192.1% | −190.5% | −250.9% | — |
| Capex / revenue | 26.9% | 33.7% | 39.9% | 32.2% | 42.2% | 46.7% | 29.8% | 30.1% | 55.2% | 41.8% | 60.0% | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
KMTS cash generation
In fiscal 2026 (ended April 30, 2026), Kestra Medical Technologies generated -$81.7 million of cash from operations and spent $34.9 million on capital expenditures, leaving free cash flow of -$116.6 million, −122.6% of revenue. It returned $3.1 million to shareholders through dividends ($0.3 million) and net share buybacks ($2.8 million). Cash and equivalents fell by $137.9 million over the year.
Related: KMTS income statement, KMTS balance sheet. See the KMTS stock overview for the latest quote and news.
KMTS cash flow FAQ
What is Kestra Medical Technologies's free cash flow?
Kestra Medical Technologies's free cash flow was -$116.6 million in fiscal 2026: -$81.7 million of operating cash flow minus $34.9 million of capital expenditures It was -$101.2 million a year earlier..
How much cash does Kestra Medical Technologies generate from operations?
Kestra Medical Technologies generated -$81.7 million of cash from operating activities in fiscal 2026.
How much does Kestra Medical Technologies spend on capital expenditures?
Kestra Medical Technologies spent $34.9 million on capital expenditures in fiscal 2026, 36.7% of revenue, compared with $23.6 million the year before.
How much stock does Kestra Medical Technologies buy back?
Kestra Medical Technologies spent $2.8 million on net share repurchases in fiscal 2026.
How much does Kestra Medical Technologies pay in dividends?
Kestra Medical Technologies paid $0.3 million in dividends in fiscal 2026.